Novartis’ Sandoz may only have one biosimilar on the U.S. market right now. But come 2020, that number will be up to 5 between the U.S. and other “key geographies,” it says.
The generics giant ($NVS) is aiming to have 11 biosimilar regulatory filings in the can by the end of next year–and it expects those to result in thumbs ups for copies of megablockbusters Enbrel from Amgen and Pfizer, Humira from AbbVie, Neulasta from Amgen ($AMGN), Remicade from Johnson & Johnson ($JNJ) and Merck ($MRK), and Rituxan from Roche ($RHHBY), it said in a Monday statement.
While it’s an ambitious goal–especially considering the U.S. market currently boasts just one biosimilar med–6 of those 11 filings are already on the books, Sandoz said. Most recently, European regulators accepted an application for a copy of cancer star Rituxan….
Source: FiercePharma